XML 90 R74.htm IDEA: XBRL DOCUMENT
v3.22.0.1

Goodwill and Other Intangible Assets (Product Rights and License by Therapeutic Category) (Details) - USD ($) $ in Millions | Dec. 31, 2021 | Dec. 31, 2020
--- | --- | ---
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items] |  |
Finite-lived intangible assets, net | $ 26,087.7 | $ 29,602.5
Product rights and licenses |  |
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items] |  |
Finite-lived intangible assets, net | 26,084.5 | 29,598.7
Product rights and licenses | Developed Markets |  |
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items] |  |
Finite-lived intangible assets, net | 14,313.6 | 17,514.5
Product rights and licenses | Greater China |  |
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items] |  |
Finite-lived intangible assets, net | 6,115.0 | 4,385.0
Product rights and licenses | JANZ |  |
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items] |  |
Finite-lived intangible assets, net | 1,495.8 | 2,803.2
Product rights and licenses | Emerging Markets |  |
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items] |  |
Finite-lived intangible assets, net | 4,160.1 | 4,896.0
Product rights and licenses | Brands |  |
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items] |  |
Finite-lived intangible assets, net | 21,146.0 | 22,216.1
Product rights and licenses | Brands | Developed Markets |  |
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items] |  |
Finite-lived intangible assets, net | 10,066.6 | 10,988.1
Product rights and licenses | Brands | Greater China |  |
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items] |  |
Finite-lived intangible assets, net | 6,102.9 | 4,372.3
Product rights and licenses | Brands | JANZ |  |
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items] |  |
Finite-lived intangible assets, net | 1,174.8 | 2,377.0
Product rights and licenses | Brands | Emerging Markets |  |
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items] |  |
Finite-lived intangible assets, net | 3,801.7 | 4,478.7
Product rights and licenses | Complex Gx and Biosimilars |  |
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items] |  |
Finite-lived intangible assets, net | 228.3 | 274.8
Product rights and licenses | Complex Gx and Biosimilars | Developed Markets |  |
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items] |  |
Finite-lived intangible assets, net | 226.8 | 272.5
Product rights and licenses | Complex Gx and Biosimilars | Greater China |  |
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items] |  |
Finite-lived intangible assets, net | 0.0 | 0.0
Product rights and licenses | Complex Gx and Biosimilars | JANZ |  |
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items] |  |
Finite-lived intangible assets, net | 1.5 | 2.3
Product rights and licenses | Complex Gx and Biosimilars | Emerging Markets |  |
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items] |  |
Finite-lived intangible assets, net | 0.0 | 0.0
Product rights and licenses | Generics |  |
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items] |  |
Finite-lived intangible assets, net | 4,710.2 | 7,107.8
Product rights and licenses | Generics | Developed Markets |  |
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items] |  |
Finite-lived intangible assets, net | 4,020.2 | 6,253.9
Product rights and licenses | Generics | Greater China |  |
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items] |  |
Finite-lived intangible assets, net | 12.1 | 12.7
Product rights and licenses | Generics | JANZ |  |
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items] |  |
Finite-lived intangible assets, net | 319.5 | 423.9
Product rights and licenses | Generics | Emerging Markets |  |
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items] |  |
Finite-lived intangible assets, net | $ 358.4 | $ 417.3

X
- Definition Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 926 -SubTopic 20 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275 + Details
Name: | us-gaap_FiniteLivedIntangibleAssetsNet
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition [Line Items] for Schedule of Product Rights and Licenses by Therapeutic Class + References No definition available. + Details
Name: | vtrs_ScheduleOfProductRightsAndLicensesByTherapeuticClassLineItems
Namespace Prefix: | vtrs_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=vtrs_DevelopedMarketsSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=vtrs_GreaterChinaSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=vtrs_JapanAustraliaAndNewZealandSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=vtrs_EmergingMarketsSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=vtrs_BrandsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=vtrs_ComplexGXAndBiosimilarsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=vtrs_GenericsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |